| Date: 25/08/2021_ | |
|----------------------|--|
| Your Name: Alan Y | eung |
| Manuscript Title: P | opulation-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among |
| people who inject of | Irugs |
| Manuscript number | r (if known): JHEPAT-D-21-01116 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | National Institute for Health Research (NIHR) | Research grant awarded to Institution |
| | medical writing, article processing charges, etc.) No time limit for this item. | Public Health Scotland | Research grant awarded to Institution |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | None | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|----|--|------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, | None | |
| | speakers bureaus, manuscript writing or educational events | | |
| 6 | Payment for expert testimony | None | |
| | | | |
| 7 | Support for attending meetings and/or travel | None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | None | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or | None | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | None | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | None | |
| 11 | Stock of Stock options | None | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | None | |
| | writing, gifts or other | | |
| 12 | services Other financial or non- | None | |
| 13 | financial interests | None | |
| | | | |
| | | | |

| Date: 06/09/2021_ | |
|----------------------|--|
| Your Name: David | Goldberg |
| Manuscript Title: P | opulation-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among |
| people who inject of | Irugs |
| Manuscript numbe | r (if known): JHEPAT-D-21-01116 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | National Institute for Health Research (NIHR) | Research grant awarded to Institution |
| | medical writing, article processing charges, etc.) No time limit for this item. | Public Health Scotland | Research grant awarded to Institution |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | None | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|----|---|------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | None | |
| | manuscript writing or educational events | | |
| 6 | Payment for expert testimony | None | |
| | | | |
| 7 | Support for attending meetings and/or travel | None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | None | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or | None | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | None | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical writing, gifts or other | | |
| 12 | services | News | |
| 13 | Other financial or non- financial interests | None | |
| | | | |

| Date: 06/09/2021 | |
|----------------------|---|
| Your Name: John F I | Dillon |
| Manuscript Title: Po | pulation-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among |
| people who inject d | rugs |
| Manuscript number | (if known): IHFPAT-D-21-01116 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | National Institute for Health Research (NIHR) | Research grant awarded to Institution |
| | medical writing, article processing charges, etc.) No time limit for this item. | Public Health Scotland | Research grant awarded to Institution |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | Gilead | Grant outside the submitted work |
| | in item #1 above). | Abbvie | Grant outside the submitted work |
| | | MSD | Grant outside the submitted work |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|----|---|--------|--------------------------------------|
| - | consulting rees | None | |
| | | | |
| _ | | | |
| 5 | Payment or honoraria for lectures, presentations, | Gilead | Honoraria outside the submitted work |
| | speakers bureaus, | Abbvie | Honoraria outside the submitted work |
| | manuscript writing or educational events | MSD | Honoraria outside the submitted work |
| 6 | Payment for expert testimony | None | |
| | | | |
| 7 | Support for attending meetings and/or travel | None | |
| | g , | | |
| | | | |
| 8 | Patents planned, issued or pending | None | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or | None | |
| | Advisory Board | | |
| | | | |
| 10 | Leadership or fiduciary role in other board, society, | None | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | None | |
| 11 | Stock of Stock options | None | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- financial interests | None | |
| | | | |
| | | | |

| Date: 06/09/2021 | |
|----------------------|---|
| Your Name: Kate Te | mpleton |
| Manuscript Title: Po | pulation-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among |
| people who inject d | rugs |
| Manuscrint number | (if known): IHEPAT-D-21-01116 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | National Institute for Health Research (NIHR) | Research grant awarded to Institution |
| | medical writing, article processing charges, etc.) No time limit for this item. | Public Health Scotland | Research grant awarded to Institution |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | GenMark | Grant outside the submitted work |
| | in item #1 above). | Cepheid | Grant outside the submitted work |
| | | Qiagen | Grant outside the submitted work |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|----|---|--------|--|
| | 0 111 | | |
| | | | |
| 5 | Payment or honoraria for | SpeedX | |
| 3 | lectures, presentations, | SpeedX | |
| | speakers bureaus, manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert testimony | None | |
| | | | |
| 7 | Support for attending meetings and/or travel | None | |
| | meetings and/or travel | | |
| | | | |
| 8 | Patents planned, issued or pending | None | |
| | | | |
| 0 | Participation on a Data | None | |
| 9 | Participation on a Data Safety Monitoring Board or | None | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| 10 | in other board, society, | None | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | None | |
| 11 | Stock of Stock options | None | |
| | | | |
| 12 | Receipt of equipment, | None | |
| 12 | materials, drugs, medical | None | |
| | writing, gifts or other | | |
| 13 | services Other financial or non- | None | |
| 13 | financial interests | None | |
| | | | |
| | | | |

| Date: 06/09/2021_ | |
|---------------------|--|
| Your Name: Matth | ew Hickman |
| Manuscript Title: F | opulation-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among |
| people who inject | drugs |
| Manuscript number | r (if known): JHEPAT-D-21-01116 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | National Institute for Health Research (NIHR) | Research grant awarded to Institution |
| | medical writing, article processing charges, etc.) No time limit for this item. | Public Health Scotland | Research grant awarded to Institution |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | None | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|----|---|------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | None | |
| | manuscript writing or educational events | | |
| 6 | Payment for expert testimony | None | |
| | | | |
| 7 | Support for attending meetings and/or travel | None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | None | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or | None | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | None | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical writing, gifts or other | | |
| 12 | services | News | |
| 13 | Other financial or non- financial interests | None | |
| | | | |

| Date: 24/08/2021_ | |
|----------------------|--|
| Your Name: Norah | Palmateer |
| Manuscript Title: P | opulation-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among |
| people who inject of | rugs |
| Manuscript numbe | r (if known): JHEPAT-D-21-01116 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | National Institute for Health Research (NIHR) | Research grant awarded to Institution |
| | medical writing, article processing charges, etc.) No time limit for this item. | Public Health Scotland | Research grant awarded to Institution |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | x None | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | x None | |

| 4 | Consulting fees | _x None | |
|----|---|---------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or | x None | |
| 6 | Payment for expert testimony | _x None | |
| 7 | Support for attending | _x None | |
| , | meetings and/or travel | None | |
| | | | |
| 8 | Patents planned, issued or pending | x None | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or | _x None | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | x None | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | x None | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | _x None | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- financial interests | _x None | |
| | | | |
| | | | |

| Date: 26/8/2021 | |
|---|---|
| Your Name: Peter Hayes | |
| Manuscript Title: Population-level estima | ites of hepatitis C reinfection post scale-up of direct-acting antivirals among |
| people who inject drugs | |
| Manuscript number (if known): JHEPAT- | D-21-01116 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | National Institute for Health Research (NIHR) | Research grant awarded to Institution |
| | medical writing, article processing charges, etc.) No time limit for this item. | Public Health Scotland | Research grant awarded to Institution |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | None | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|----|--|---|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | Falk, Ferring, Gore, Lundbeck, Norgine | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| | | | |
| 8 | Patents planned, issued or pending | None | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or | Abbvie,BMS, Eisai Ltd, Ferring, Gilead, Janssen, | |
| | Advisory Board | MSD, Norvartis, ONO | |
| 10 | Leadership or fiduciary role in other board, society, | None | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | None | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- financial interests | None | |
| | | | |
| | | | |

| Date: 26/8/2021 | |
|---------------------------|--|
| Your Name: Rory Gunson | |
| Manuscript Title: Populat | ion-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among |
| people who inject drugs_ | |
| Manuscript number (if kn | own): IHFPAT-D-21-01116 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | National Institute for Health Research (NIHR) | Research grant awarded to Institution |
| | medical writing, article processing charges, etc.) No time limit for this item. | Public Health Scotland | Research grant awarded to Institution |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | None | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|----|---|------|--|
| | | | |
| 5 | Payment or honoraria for | None | |
| 3 | lectures, presentations, | None | |
| | speakers bureaus, manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert testimony | None | |
| | | | |
| 7 | Support for attending meetings and/or travel | None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | None | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or | None | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | None | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- financial interests | None | |
| | maneiai micrests | | |
| | | | |

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

| Date: 06/09/2021_ | |
|----------------------|--|
| Your Name: Stephe | n Barclay |
| Manuscript Title: Po | opulation-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among |
| people who inject d | rugs |
| Manuscript number | (if known): JHEPAT-D-21-01116 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | National Institute for Health Research (NIHR) | Research grant awarded to Institution |
| | medical writing, article processing charges, etc.) No time limit for this item. | Public Health Scotland | Research grant awarded to Institution |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | Gilead | Grant outside the submitted work |
| | in item #1 above). | Abbvie | Grant outside the submitted work |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|----|---|--------|--|
| 4 | Consulting rees | Notie | |
| | | | |
| | | | |
| 5 | Payment or honoraria for lectures, presentations, | Gilead | Personal fees outside the submitted work |
| | speakers bureaus, | Abbvie | Personal fees outside the submitted work |
| | manuscript writing or educational events | | |
| 6 | Payment for expert testimony | None | |
| | | | |
| 7 | Support for attending meetings and/or travel | None | |
| | gc aa, c. a.e.c. | | |
| | | | |
| 8 | Patents planned, issued or pending | None | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or | None | |
| | Advisory Board | | |
| | | | |
| 10 | Leadership or fiduciary role in other board, society, | None | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | None | |
| 11 | Stock of Stock options | None | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | None | |
| 13 | financial interests | Notic | |
| | | | |
| | | | |

| Date: 26/8/2021 |
|---|
| Your Name: Sharon Hutchinson |
| Manuscript Title: Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among |
| people who inject drugs |
| Manuscript number (if known): JHEPAT-D-21-01116 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | National Institute for Health Research (NIHR) | Research grant awarded to Institution |
| | medical writing, article processing charges, etc.) No time limit for this item. | Public Health Scotland | Research grant awarded to Institution |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | None | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|----|--|--------|---|
| | Ü | | |
| | | | |
| 5 | Payment or honoraria for | Gilead | Honoraria to S Hutchinson for presentation at |
| | lectures, presentations, | | symposium |
| | speakers bureaus, | | |
| | manuscript writing or educational events | | |
| 6 | Payment for expert testimony | None | |
| | | | |
| 7 | Support for attending meetings and/or travel | None | |
| | meetings and/or traver | | |
| | | | |
| 8 | Patents planned, issued or pending | None | |
| | | | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or | None | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| 10 | in other board, society, | None | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | None | |
| | Stock of Stock options | None | |
| | | | |
| 12 | Receipt of equipment, | None | |
| 12 | materials, drugs, medical | | |
| | writing, gifts or other | | |
| 13 | services Other financial or non- | None | |
| 13 | financial interests | None | |
| | | | |
| | | | |

| Date: 25/08/2021 | |
|-------------------|---|
| Your Name: Scott | A McDonald |
| Manuscript Title: | Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among |
| people who inject | drugs |
| Manuscript numb | er (if known): JHEPAT-D-21-01116 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | National Institute for Health Research (NIHR) | Research grant awarded to Institution |
| | medical writing, article processing charges, etc.) No time limit for this item. | Public Health Scotland | Research grant awarded to Institution |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | None | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|----|--|------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, | None | |
| | speakers bureaus, manuscript writing or educational events | | |
| 6 | Payment for expert testimony | None | |
| | | | |
| 7 | Support for attending meetings and/or travel | None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | None | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or | None | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | None | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | None | |
| 11 | Stock of Stock options | None | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | None | |
| | writing, gifts or other | | |
| 12 | services Other financial or non- | None | |
| 13 | financial interests | None | |
| | | | |
| | | | |

| Date: 31/08/2021 | |
|--|-----|
| Your Name: Shanley Smith | |
| Manuscript Title: Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals am | ong |
| people who inject drugs | |
| Manuscript number (if known): JHEPAT-D-21-01116 | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | National Institute for Health Research (NIHR) | Research grant awarded to Institution |
| | medical writing, article processing charges, etc.) No time limit for this item. | Public Health Scotland | Research grant awarded to Institution |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | None | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|----|--|------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, | None | |
| | speakers bureaus, manuscript writing or educational events | | |
| 6 | Payment for expert testimony | None | |
| | | | |
| 7 | Support for attending meetings and/or travel | None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | None | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or | None | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | None | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | None | |
| 11 | Stock of Stock options | None | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | None | |
| | writing, gifts or other | | |
| 12 | services Other financial or non- | None | |
| 13 | financial interests | None | |
| | | | |
| | | | |